These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 36500441)

  • 1. Research Progress on Small Molecular Inhibitors of the Type 3 Secretion System.
    Lv C; Li Y; Wei Y; Wang J; Yu H; Gao F; Zhu C; Jia X; Tong M; Dong P; Gao Q; Geng L
    Molecules; 2022 Nov; 27(23):. PubMed ID: 36500441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Inhibitors of the Type III Secretion System.
    Gu L; Zhou S; Zhu L; Liang C; Chen X
    Molecules; 2015 Sep; 20(9):17659-74. PubMed ID: 26404233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiota and Pathogen Proteases Modulate Type III Secretion Activity in Enterohemorrhagic Escherichia coli.
    Cameron EA; Curtis MM; Kumar A; Dunny GM; Sperandio V
    mBio; 2018 Dec; 9(6):. PubMed ID: 30514785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Targets and Strategies for Inhibition of the Bacterial Type III Secretion System (T3SS); Inhibitors Directly Binding to T3SS Components.
    Hotinger JA; Pendergrass HA; May AE
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33669653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The type III secretion system needle, tip, and translocon.
    Dey S; Chakravarty A; Guha Biswas P; De Guzman RN
    Protein Sci; 2019 Sep; 28(9):1582-1593. PubMed ID: 31301256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing Cyclic Peptomers as Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria.
    Lam HN; Lau T; Lentz A; Sherry J; Cabrera-Cortez A; Hug K; Lalljie A; Engel J; Lokey RS; Auerbuch V
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0169020. PubMed ID: 33875435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type III Secretion in the Melioidosis Pathogen
    Vander Broek CW; Stevens JM
    Front Cell Infect Microbiol; 2017; 7():255. PubMed ID: 28664152
    [No Abstract]   [Full Text] [Related]  

  • 8. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.
    Keyser P; Elofsson M; Rosell S; Wolf-Watz H
    J Intern Med; 2008 Jul; 264(1):17-29. PubMed ID: 18393958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical inhibitors of the type three secretion system: disarming bacterial pathogens.
    Duncan MC; Linington RG; Auerbuch V
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5433-41. PubMed ID: 22850518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shutting Down Shigella Secretion: Characterizing Small Molecule Type Three Secretion System ATPase Inhibitors.
    Case HB; Mattock DS; Dickenson NE
    Biochemistry; 2018 Dec; 57(50):6906-6916. PubMed ID: 30460850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches targeting the type III secretion system to treat or prevent bacterial infections.
    Charro N; Mota LJ
    Expert Opin Drug Discov; 2015 Apr; 10(4):373-87. PubMed ID: 25727140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topological Analysis of the Type 3 Secretion System Translocon Pore Protein IpaC following Its Native Delivery to the Plasma Membrane during Infection.
    Russo BC; Duncan JK; Goldberg MB
    mBio; 2019 May; 10(3):. PubMed ID: 31138750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Cyclic Peptomers as Type III Secretion System Inhibitors.
    Lam H; Schwochert J; Lao Y; Lau T; Lloyd C; Luu J; Kooner O; Morgan J; Lokey S; Auerbuch V
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Injectisome, a Complex Nanomachine for Protein Injection into Mammalian Cells.
    Lara-Tejero M; Galán JE
    EcoSal Plus; 2019 Mar; 8(2):. PubMed ID: 30942149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 3 secretion system as an anti-Pseudomonal target.
    Horna G; Ruiz J
    Microb Pathog; 2021 Jun; 155():104907. PubMed ID: 33930424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting bacterial pathogenesis by inhibiting virulence-associated Type III and Type IV secretion systems.
    Blasey N; Rehrmann D; Riebisch AK; Mühlen S
    Front Cell Infect Microbiol; 2022; 12():1065561. PubMed ID: 36704108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type III secretion systems and disease.
    Coburn B; Sekirov I; Finlay BB
    Clin Microbiol Rev; 2007 Oct; 20(4):535-49. PubMed ID: 17934073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of phenolic compounds that suppress the virulence of Xanthomonas oryzae on rice via the type III secretion system.
    Fan S; Tian F; Li J; Hutchins W; Chen H; Yang F; Yuan X; Cui Z; Yang CH; He C
    Mol Plant Pathol; 2017 May; 18(4):555-568. PubMed ID: 27084974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A global survey of bacterial type III secretion systems and their effectors.
    Hu Y; Huang H; Cheng X; Shu X; White AP; Stavrinides J; Köster W; Zhu G; Zhao Z; Wang Y
    Environ Microbiol; 2017 Oct; 19(10):3879-3895. PubMed ID: 28401683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-Labeling Enzyme Tags for Analyses of Translocation of Type III Secretion System Effector Proteins.
    Göser V; Kommnick C; Liss V; Hensel M
    mBio; 2019 Jun; 10(3):. PubMed ID: 31239375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.